General MedicationsINTRAVENOUSGeneric
ALIQOPA
COPANLISIB DIHYDROCHLORIDE
Standard Dose
60MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ALIQOPA is listed in Drugs@FDA under application 209936 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient COPANLISIB DIHYDROCHLORIDE Form and strength POWDER;INTRAVENOUS - 60MG/VIAL Sponsor BAYER HEALTHCARE Submission history Latest submission status date: 2023-09-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview ALIQOPA is listed in Drugs@FDA under application 209936 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient COPANLISIB DIHYDROCHLORIDE Form and strength POWDER;INTRAVENOUS - 60MG/VIAL Sponsor BAYER HEALTHCARE Submission history Latest submission status date: 2023-09-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.